Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

NSCLC 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

tipifarnib 1 osimertinib 1 aflutinib 1 CP protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NSCLC × tipifarnib × Clear all

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Kura Oncology, Inc.

Phase 1 Withdrawn

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡